EL DORADO, Ark., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium company, ...
Early results from 4,000 babies show that genome sequencing picks up many more serious health conditions than standard newborn screening and is favored by most parents. Early results from a study of ...
The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific ...
Please provide your email address to receive an email when new articles are posted on . Amivantamab-vmjw plus lazertinib significantly improved OS for certain patients with advanced NSCLC compared ...
Mona Bafadhel receives funding from the National Institute of Health Research, Asthma+Lung UK, and Horizon Europe. For this study, Mona Bafadhel received funding from AstraZeneca to complete the study ...
Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 ...
Editor’s Note: The publisher of the study referenced in this story has flagged the report with “expressions of concern.” This story may be updated when the journal posts further information. Women who ...
A small proof-of-concept study of robotic-assisted cataract surgery reports successful outcomes with no treatment-related ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback